SCHEMBL4113188

SCHEMBL4113188

Nc1nc(N2CCOCC2)c2nc(-c3ccsc3)ccc2n1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.51
NOS1 P29475 2/20 0.47
HRH4 Q9H3N8 2/20 0.47
HRH1 P35367 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
PIK3CA P42336 7/20 0.43
MTOR P42345 4/20 0.43
PIK3CG P48736 4/20 0.43
PIK3CD O00329 5/20 0.42
GAK O14976 2/20 0.42
PRKDC P78527 3/20 0.41
DHFR P00374 1/20 0.38
NEK2 P51955 1/20 0.38
PIK3CB P42338 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4107831 0.84 NOS1 (0.53) ARNOS1HRH4PIK3CAMTOR
SCHEMBL4528710 0.83 PIK3CD (0.54) NOS1HRH4PIK3CAMTORPIK3CG
SCHEMBL3760139 0.82 NOS1 (0.72) ARNOS1HRH4HRH1HRH3
SCHEMBL4101991 0.81 NOS1 (0.52) NOS1PIK3CAMTORPIK3CGPIK3CD
SCHEMBL4114309 0.81 NOS1 (0.52) ARNOS1PIK3CAMTORPIK3CG
SCHEMBL4116775 0.79 NPC1 (0.51) NOS1HRH4PIK3CAMTORPIK3CG
SCHEMBL4119392 0.79 PIK3CA (0.58) NOS1HRH4PIK3CAMTORPIK3CG
SCHEMBL4114399 0.78 NOS1 (0.47) NOS1PIK3CAMTORPIK3CGPIK3CD
SCHEMBL4107655 0.78 AR (0.50) ARNOS1HRH4PIK3CAMTOR
SCHEMBL4119557 0.78 NOS1 (0.46) NOS1HRH4PIK3CAMTORPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232278-B2 Pyrido(3,2-D)pyrimidines and pharmaceutical compositions useful for treating hepatitis C GILEAD SCIENCES, INC. (US) 2012-07-31 US disclosed
US-20090264415-A2 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2009-10-22 US disclosed
US-20090131414-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C GILEAD SCIENCES, INC. (US) 2009-05-21 US disclosed
US-20090036430-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2009-02-05 US disclosed
EP-1899332-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C. GILEAD SCIENCES, INC. (US) 2008-03-19 EP disclosed
US-20080004285-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT 4 AZA IP NV (BE) 2008-01-03 US disclosed
WO-2006135993-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C. GILEAD SCIENCES, INC. (US) 2006-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131414-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR TREATING HEPATITIS C DPYD, TYMP, PNPO AR 4757/4885NOS1 4251/4885HRH4 1280/4885
US-20080004285-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT PNPO, TYMP, PNP AR 1342/4885NOS1 334/4885HRH4 2398/4885
US-20090036430-A1 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT PNPO, TYMP, PNP AR 1342/4885NOS1 334/4885HRH4 2398/4885
US-20090264415-A2 PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT PNPO, TYMP, PNP AR 1342/4885NOS1 334/4885HRH4 2398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.